Shin Nippon Biomedical Laboratories, Ltd.

In contrast to the prodigious novel approval counts of 2023, the US FDA started the new year in a more abstemious fashion. After approving Ligand Pharmaceuticals, Inc. ’s new molecular entity Zelsuvm

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. SNBL To Pay 28% Premium To Re-Acquire S

In a setback for the Japanese bioventure, AnGes, Inc. has discontinued a government-supported R&D project for an injected DNA plasmid vaccine for the original Wuhan strain of COVID-19. While the Osa

Verve Therapeutics launched with $58.5m in series A venture capital, a high-profile CEO from academia and a big goal – what some might even call a biopharmaceutical holy grail – to prevent coronary h